A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Status Terminated

Clinical Trial Summary

This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome. Following wash-out (if needed), all eligible subjects will enter an open-label intra-subject dose-escalation period of 8 weeks' duration, followed either by a double-blind randomized withdrawal period of 4 weeks' duration (if the subject meets randomization criteria) or by an additional open label dosing period of 4 weeks' duration (if the subject does not meet randomization criteria).It is anticipated that the overall duration of the study per subject will range from approximately 16-22 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03053271
Study type	Interventional
Source	Millendo Therapeutics, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	April 13, 2017
Completion date	August 12, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT05881005` - NAC- NAFLD And Cushing	N/A
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Terminated	`NCT03379363` - Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Recruiting	`NCT06008184` - Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Recruiting	`NCT05911620` - Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism	N/A
Completed	`NCT02934399` - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting	`NCT04045015` - Liquorice and Salivary Cortisol	N/A
Recruiting	`NCT05804669` - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	Phase 1/Phase 2
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting	`NCT03343470` - The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
Recruiting	`NCT03364803` - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Terminated	`NCT02001051` - Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism	Phase 2
Completed	`NCT03697109` - A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome	Phase 3
Enrolling by invitation	`NCT03604198` - Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome	Phase 2
Completed	`NCT05347979` - Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants	Phase 1
Recruiting	`NCT01382420` - Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma	N/A
Completed	`NCT00001849` - New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome	Phase 2
Recruiting	`NCT06229405` - Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
Recruiting	`NCT03211624` - Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome